Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.

doi:10.1200/JCO.2017.73.7999

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2018

Fernandez Conrad V, Mullen Elizabeth A, Chi Yueh-Yun, Ehrlich Peter F, Perlman Elizabeth J, Kalapurakal John A, Khanna Geetika, Paulino Arnold C, Hamilton Thomas E, Gow Kenneth W, Tochner Zelig, Hoffer Fredric A, Withycombe Janice S, Shamberger Robert C, Kim Yeonil, Geller James I, Anderson James R, Grundy Paul E, Dome Jeffrey S

Abstract excerpt

Background The National Wilms Tumor Study (NWTS) approach to treating stage III favorable-histology Wilms tumor (FHWT) is Regimen DD4A (vincristine, dactinomycin, and doxorubicin) and radiation therapy. Further risk stratification is required to improve outcomes and reduce late effects. We evaluated clinical and biologic variables for patients with stage III FHWT without combined loss of heterozygosity (LOH) at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Pair 16

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dactinomycin

Share to Doxorubicin

Share to Nephrectomy

Share to Progression-Free Survival

Share to Radiation Dosage

Share to Vincristine

Share to Wilms Tumor

Source

Open in PubMed Open full text

Identifiers

PMID: 29211618
DOI: 10.1200/JCO.2017.73.7999
PMCID: PMC5773840

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.PMID 29211618Read ↗

Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.Semantic proximity Read ↗

Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study GroupSemantic proximity Read ↗

Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.Semantic proximity Read ↗

Subsets of Very Low Risk Wilms Tumor Show Distinctive Gene Expression, Histologic, and Clinical FeaturesSemantic proximity Read ↗

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.Semantic proximity Read ↗

Cyclin B1 is a novel prognostic biomarker and promotes proliferation, migration and invasion in Wilms TumourSemantic proximity Read ↗

Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533Semantic proximity Read ↗

Multi-Omics and Machine Learning Integration of Diverse Cell Death Pathways Optimize Risk Stratification and Inform Drug Therapy in Wilms TumorSemantic proximity Read ↗

Second generation of AHOPCA (Asociación de Hemato-Oncología Pediátrica de Centro América) treatment guidelines for Wilms tumor: a report of outcomesSemantic proximity Read ↗

Long-term outcomes and patterns of relapse in patients with bilateral Wilms tumor or bilaterally predisposed unilateral Wilms tumor, a report from the COG AREN0534 study.Semantic proximity Read ↗

Prognostic Determinants of Survival, Relapse, and Chemoresistance in Unilateral Wilms Tumor: A 10-Year Real-World Cohort Study from the Caucasus RegionSemantic proximity Read ↗

Cytogenetic abnormalities and clinical outcome in Wilms tumor: A study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group†Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.